新青年麻醉论坛

 找回密码
 会员注册

QQ登录

只需一步,快速开始

快捷登录

搜索
热搜: 麻醉 视频 中级
楼主: rextao
打印 上一主题 下一主题

[医护心情] rextao的华西麻醉研究生成长历程—我也开博(就在这个麻醉的天堂)

[复制链接]
121#
 楼主| 发表于 2009-4-1 12:24:35 | 只看该作者

愚人节这天开始下临床了

上了差不多一年的临床了,也该准备实验了 今天开始下临床看文献···设计实验 时机成熟到实验室开始···
122#
 楼主| 发表于 2009-4-2 10:03:16 | 只看该作者

中心静脉穿刺并发症及其预防措施

1.气胸
  无论是颈内静脉或是锁骨下静脉穿刺时都有穿破胸膜和肺尖的可能。
原因:锁骨下进路时,针干与皮肤角度太大使针尖离开锁骨下缘,很易穿破胸膜和肺。颈内静脉穿刺时,为避开颈总动脉而针尖指向过于偏外,往往会穿破胸膜顶和肺尖。
处理:如果仅为一针眼产生少量气胸不需特殊处理,可自行吸收。如果针尖在深部改变方向使破口扩大再加上正压机械通气,气胸会急剧加重甚至形成张力性气胸,这时应提醒外科医生在劈开胸骨后打开胸膜,并处理肺部破口。
    2.血胸
  锁骨下进路穿刺时,进针过深,易误伤锁骨下动脉,这时应立即撤针并从锁骨上压迫止血,若同时穿破胸膜势必会引起血胸。此时应改换穿刺点或经锁骨上路穿刺锁骨下静脉。颈内静脉穿刺尤其易损伤动脉,只要及时退针局部压迫3-5分钟即可止血,不致造成严重后果。
    3.液胸
  无论是颈内静脉还是锁骨下静脉穿刺时,在送管时将穿透静脉而送入胸腔内,此时液体都输入胸腔内。
表现:从此路给药(麻醉药,肌松药等)均无效;测量中心静脉压时出现负压(体外循环前不应出现负压); 此路输液通畅但抽不出回血。
处理:若出现上述现象应确诊导管在胸腔内,不应再使用此通路,应另行穿刺置管。原导管不宜当时拔出,应开胸后在外科医生监视下拔除原导管,必要时从胸腔内缝合止血。
    4.空气栓塞
  穿刺前未使病人头低位,如病人处于低血容量状态,当穿中静脉后一旦撤掉注射器与大气相通,由于心脏的舒张而将空气吸入心脏。后天性心脏病(无心内分流)的病人进入少量空气不致引起严重后果。有心内分流的先天性心脏病病人(尤其是右向左分流的紫绀病人)可能引起严重后果,穿刺时应注意避免。
    5.心肌穿孔
  由于导管太硬且送管太深直至右房,由于心脏的收缩而穿破心房壁(也有穿破右室壁的报道),在心脏直视手术切开心包即能发现,给予适当处理即可。但在非心脏手术或是抢救危重病人时常常引起心包填塞,如不能及时发现作出正确诊断,后果十分严重,死亡率很高。
预防方法:不用劣质导管,送管不宜过深,一般送入8-10cm即可。
    6.感染
原因:
⑴导管消毒不彻底;
⑵穿刺过程中无菌操作不严格;
⑶术后护理不当;
⑷导管留置过久。
预防方法:在病情允许的情况下留置时间越短越好;若病情需要最长7-10天应该拔除或重新穿刺置管。

友情提示:转载请注意注明作者和出处!!

123#
 楼主| 发表于 2009-4-2 10:09:26 | 只看该作者

CVP穿刺术—颈内静脉穿刺

中心静脉压(CVP)或右房压是指血液在右心室舒张充盈期被推送进入心室时的压力。放置CVP监测导管的指征包括:测量中心静脉压,了解病人的循环血容量和心脏功能;快速输血输液抢救大出血、低血容量性休克; 经静脉紧急放置起搏器;缺乏足够的外周静脉,以及长时间输注高张力的液体(如全胃肠外营养)或对外周血管有刺激性的药物(如氯化钾和多巴胺);现代麻醉监测和治疗中,角色的多样性,即术前预测术中可能出现血流动力学剧烈波动,或手术时间较长,术中有大量液体置换时,在麻醉诱导后置入中心静脉导管,必要时置入右心漂浮导管。

中心静脉穿刺常选择颈内静脉和锁骨下静脉,也有选择股静脉进行操作。

(一) 颈内静脉
  颈内静脉的解剖特点:起源于颅底;全程均被胸锁乳突肌覆盖;上部位于胸锁乳突肌前沿内侧; 中部位于胸锁乳突肌锁骨头前缘的下面和颈总动脉后外侧;下行至胸锁关节处于锁骨下静脉汇合成无名静脉;再下行与对侧无名静脉汇合成上腔静脉进入右心房。颈内静脉穿刺特点:成人颈内静脉较粗大,易被穿中; 右侧无胸导管而且右颈内静脉至无名静脉入上腔静脉段几乎为一直线;右侧胸膜顶较左侧为低;临床上常选用右侧颈内静脉穿刺置管,尤其是放置Swan-Ganz导管更为方便。
  颈内静脉穿刺的进针点和方向根据个人的习惯各有不同,一般根据颈内静脉与胸锁乳突肌的关系,可分别在胸锁乳突肌的前、中、后三个部位进针。
  ⑴前路颈内静脉穿刺
  病人仰卧头低位,右肩部垫起,头后仰使颈部充分伸展,面部略转向对侧。操作者以左手食指和中指在中线旁开3cm,于胸锁乳突肌的中点前缘相当于甲状软骨上缘水平触及颈总动脉搏动,并向内侧推开颈总动脉,在颈总动脉外缘的0.5cm处进针,针干与皮肤成30-40°角,针尖指向同侧乳头或锁骨中内1/3交界处前进。此路进针造成气胸的机会不多,但易误入颈总动脉。
  ⑵中路颈内静脉穿刺
  在锁骨与胸锁乳突肌的锁骨头和胸骨头形成的三角区的顶点,颈内静脉正好位于此三角的中心位置,该点距锁骨上缘约3-5cm,进针时针干与皮肤呈30°角,与中线平行直接指向足端。如果试穿未成功,将针尖退到皮下,再向外偏斜10°左右,指向胸锁乳突肌锁骨头以内的后缘,常能成功。若遇肥胖、短颈或小儿,全麻后胸锁乳突肌标志常不清楚,定位会有一些困难。此时可以利用锁骨内侧,颈内静脉正好经此而下行与锁骨下静脉汇合。穿刺时以左手拇指按压,以确认此切迹,在其上方约1-1.5cm处进针,针干与中线平行,针尖指向足端,一般进针2-3cm即可进入颈内静脉。若未成功再将针退至皮下,略向外侧偏斜进针常可成功。
  ⑶后路颈内静脉穿刺
在胸锁乳突肌的后缘中下1/3的交点或在锁骨上缘3-5cm处作为进针点。在此处颈内静脉位于胸锁乳突肌的下面略偏向外侧。穿刺时面部尽量转向对侧,针干一般保持水平,在胸锁乳突肌的深部指向胸骨上窝方向前进。针尖不宜过分向内侧深入,以免损伤颈总动脉,甚至穿入气管内。
以上三种进针点一般以中路为多,直接触及颈总动脉,可以避开颈总动脉,故误伤动脉的机会较少,而且颈内静脉位置较表浅,穿中率较高。由于颈内静脉与颈总动脉相距很近,为避免误伤动脉,以确定穿刺的角度和深度,在正式穿刺前强调先用细针试穿。

有奖活动:我为论坛出谋划策!! ←点击查看详情

124#
 楼主| 发表于 2009-4-2 10:13:39 | 只看该作者

CVP穿刺术—锁骨下静脉穿刺

(二)锁骨下静脉
  锁骨下静脉的解剖特点。锁骨下静脉是腋静脉的延续,起于第1肋的外侧缘,成人长约3-4cm,前面是锁骨的内侧缘。在锁骨中点稍内位于锁骨与第1肋骨之间略向上向内呈弓形而稍向内下,向前跨过前斜角肌于胸锁关节处与颈内静脉汇合为无名静脉,再与内侧无名静脉汇合成上腔静脉。锁骨下静脉粗大,直径达2cm,走行平缓,近心脏,解剖标志明显,血管畸形罕见,易于穿中。
锁骨下静脉穿刺多选用右侧锁骨下静脉作为穿刺置管用,穿刺进路有锁骨上路和锁骨下路两种。
  ⑴经锁骨上路穿刺
  病人取仰卧头低位,右肩部垫高,头偏向对侧,使锁骨上窝显露出来。在胸锁乳突肌锁骨头的外侧缘,锁骨上缘约1.0cm处进针,针与身体正中线或与锁骨成45°角,与冠状面保持水平或稍向前15°,针尖指向胸锁关节,缓慢向前推进,且边进针边回抽,直到有暗红色血为止。当穿中静脉后将钢丝送入,用扩张器沿钢丝送入静脉内,而后撤出扩张器,再将导管沿钢丝送入静脉。导管送入的长度据病人的具体情况而定,一般5-10cm即可,但必须置于上腔静脉(SVC)或右心房。导管固定。
  锁骨上路穿刺的特点:在穿刺过程中,针尖前进的方向远离锁骨下动脉和胸膜腔,较锁骨下进路为安全。不经过肋间隙,送管时阻力小,用外套管穿刺时可直接将套管送入静脉,到位率比锁骨下路高。可经此路放置Swan-Ganz导管和肺动脉导管或心内膜起搏器。
  ⑵经锁骨下路穿刺
  病人取仰卧位,右上肢垂于体侧,略向上提肩,使锁骨与第一肋间的间隙张开便于进针。右肩部可略垫高(也可不垫),头低位约15~30°。从锁骨中内1/3的交界处,锁骨下缘约1~1.5cm 进针。针尖指向胸骨上窝,针体与胸壁皮肤的夹角小于10°,紧靠胸锁内下缘徐徐推进。在进针的过程中,边进边轻轻回抽,当有暗红色血液时停止前进,并反复测试其通畅情况,确定在静脉腔内时便可置导管。如果以此方向进针已达4~5cm仍无回血时,不可再向前推进,以免损伤锁骨下动脉。此时应徐徐向后退针并边退边抽,往往在撤针过程中抽到回血,说明已穿透锁骨下静脉。在撤针过程中仍无回血,可将针尖撤到皮下而后改变方向,使针尖指向锁骨上切迹以同样方法徐徐前进,往往可以成功。
此进路穿刺过深时有误伤锁骨下动脉的可能。如果针干与胸部皮肤角度过大有穿破胸腔和肺组织的可能。锁骨下进路置管到位率较低,导管可进入同侧颈内静脉、对侧无名静脉。心脏手术时撑开胸骨时可能影响导管的位置。

有奖活动:我为论坛出谋划策!! ←点击查看详情

125#
 楼主| 发表于 2009-4-7 14:35:32 | 只看该作者

丁香园令我感触最深的一张帖子(作者:陶教授)

本人几次回国,在美国接待国内学者,最大的感觉就是,国内现在仪器种类和药品不比美国差(虽然分布程度不一样),但理念上差别很大。这里列举一些我所知道的差异之处,供大家讨论:

1.区域麻醉过于滥用:
麻醉的三大成分是:镇痛(analgesia),不知晓(amnesia),和肌肉松弛(muscle relaxation)。理想的麻醉这三样都要做到。这正是美国现在绝大多数病人都做全麻,即使上了区域麻醉,那也是为了术后镇痛,不是单靠它来做手术。病人手术中不愿听到各种仪器声音,外科医生也不愿意病人听到自己的谈论,麻醉医生全麻后有效控制呼吸(如腹腔镜手术),大家皆大欢喜,法律起诉少,病人安全,满意度高。我也知道国内区域麻醉主要是从经济角度考虑,但有时候区域麻醉对某些病人是危险的。有一位朋友,做乳腺手术,用了硬膜外,术中呼吸困难,差点过去,其后对麻醉的恐怖心理一直没有消除。另一位朋友,鼻中隔手术,用表麻,可以想象病人在手术显微镜和外科医生的刀工器械下是多么恐怖,病人如果呛咳或烦躁乱动,又是多么危险。这样做麻醉,病人没有什么满意而言,会对麻醉很反感和恐怖,不利于树立麻醉医生的良好形象。有关费用问题,我不太清楚国内麻醉收费。在美国,大头费用在人工费,也就是麻醉医生的Professional Fees,这在全麻和区域麻是一样的。全麻所用的药可能是贵一些,但在整个住院费中比例很小。更重要的是,为了省钱,使病人经受不必要的痛苦和风险,从伦理和法律上是讲不过去的
还有一点要注意,有人认为区域麻醉比全麻安全,这是没有依据的。在很多情况下,全麻比区域麻更安全。比如,二氧化碳人工气腹,全麻可以良好地控制血气,要知道高碳酸血症对冠心病,肺动脉高压等是很危险的,血二氧化碳增高在清醒病人是很难受的。区域麻醉,除了剖宫产外,没有明显优势,应用不好,反而会成灾难。

2。 对快速诱导(Rapid Sequence Induction, RSI)理解应用不够:

RSI 是现代麻醉的重要原则。是防止病人误吸的重要手段。全麻诱导的方式,分为普通诱导(Starndard Induction)和快速诱导(RSI)。RSI 主要用以下下病人:

a。有胃食管反流者(gastroesophageal reflux disorder, GERD);
b。急腹症,机械或动力肠梗阻;
c。Full stomach 需要急诊手术;
d。所有产妇;
e。外伤(急诊,多为 full stomach,且交感兴奋,胃排空延时);
f。部分人认为糖尿病人,胃动障碍应该 RSI,但这有争议。

RSI 的具体方法是,面罩给氧,不辅助通气,事先可给胃辅助动力药(metoclopramide),和中和胃酸药(sodium citrate),喉头 Sellick 压迫,同时给诱导和快速肌松药(succinylcholine or rocuronium), 30 秒后插管。

有RSI指征得病人,一定要表明你用的上述方法。在 RSI 时用Vercuronium 是不对的,因为起效太慢,不能迅速控制气道。看到国内很多同行在饱胃,肠梗阻,或产妇用面罩加压给氧,vecuronium 诱导,很为他们捏把汗。

3。困难气道处理时,肌松药用不适当:
有些同道在没有充分估计气道难度,没有建立有效面罩通气的情况下给中效肌松剂如 vecuronium ,这在美国俗称为 burn bridges ,意指你走上了绝命路。Vecuronim 作用达20分钟,不能建立有效通气等于死亡。计算一下,正常人功能残气量2升,充分氧和后,按每分钟耗氧200毫升计,病人可以不通气坚持5-10分钟。在没有建立好通气时,你给的药物要在5-10分钟内清除,否则病人有可能死亡。能达到如此效果的诱导药物只有propofol + succinylcholine。有很多人把 succinylcholine 妖魔化(增加胃内压,颅内压等顾虑),是没有依据的。Succinylcholine 使用合理时,是你最好的朋友。没有哪一种药物能在这么快的时间内,给你完全的肌松效果,然后快速消失。当然,对它的副作用和禁忌症也要了如指掌。

4。某些药物使用有些过时,达不到效果:

经常见到同道们用多巴胺。这个药在美国除了少数肾病人用一点外,在外科和麻醉领域已经淘汰。其理由是,作用广泛但又不清楚。在需要它缩血管时,它有心肌刺激作用,导致心肌氧耗增加,心律失常。需要它的beta效果时,它又有alpha 作用,增加后负荷,效果很难说。目前,我们都选择目的清楚的药物,需要alpha, 就用 phenylephrine (alpha),norepinephrine (alpha 为主),需要beta, 就用 dobutamine, milronone, 需要混合就用 epinephrine , 或多药合用,分别调节,可攻可守,不象是给了多巴胺,不知道会发生什么事情。

地塞米松也是大家爱用的万金油。困难气道也用,低血压也用。其实激素使用的真正的指征只有糖皮质缺乏,部分神经组织手术,和部分口鼻手术。病人气道不能建立,麻烦事那么多,还在地塞米松上浪费时间?要知道,普通病人和糖尿病病人,给了激素,血糖耐受更差,对预后更不好。

碳酸氢钠的使用,会增加细胞内酸中毒,没有有效通气时,形成高碳酸血症,同时使血红蛋白曲线左移,不利组织获氧,应尽量少用。改善组织酸中毒的最佳方法是改善循环和提高血氧携带能力(fluids and blood)。

5。麻醉医生的职业规范:

我们和外科是共生关系。更严格的说,我们是为外科提供服务,否则我们没有存在的必要。我们和外科医生打交道,要有理有节。手术前要看病人,有特殊病情的,和外科医生交流,摆清事实,做出检查方案。比如,外科医生要把一个没有控制好的冠心病人安排择期手术,我们可以提出,该病人风险大,对病人,家属,你我都不利,术后并发症几率高,费用高,吃官司可能大,我们还是让内科把他病情稳定后再来吧。这样外科医生会感激和尊重你,因为他不会评估冠心病人的危险性。

此外,麻醉医生手术中不能脱岗。没有人顶替你,你就是xx 在裤子里,也不能离开病人,哪怕是局麻,这是基本的职业规范。国内有同行抱怨外科医生对他们不信任,宁可叫护士,灌注师解决问题,也不叫麻醉医生,而外科医生说这是麻醉医生很多时候不在场的结果。这多少和我们平时自己职业规范有关。

先写到这里,以后想到多的,再补充。

补充:

6。美国住院医生训练完成,就是主治医师独立负责制,你就是这台手术的最终的负责人和法律承担人。白天遇到困难,如果你不要求,别人是不会来帮你的,这是对你职业技术的信任和尊敬。夜间值班时,就你一个人。白天晚上都没有什么叫主任之说(兴许主任更不如你)。当然你可以叫人帮你,特别是气道遇到麻烦时,如ASA推荐的。
一次国内医生来参观,看到我为一个大胖子作刨宫产腰麻,折腾了好长时间,护士和产科医生就在旁边老老实实地看着。国内医生说,说这要是在国内,护士和外科医生就会嚷着换人了。
此外,我们麻醉有困难,打不进 IV ,插不进管,外科医生可以看,但未经要求和允许,他们不会主动上来帮忙。同样,他们手术出了问题,或手脚慢,我们也不会批评他们。这也是职业规范。

7。同行和上下级之间,要彼此互相学习,彼此尊重。我们在工作中经常遇到自己不熟悉或是忘记了的事。我当住院医师时,和科主任一起在产科值班。该主任是全国危重医学专家,行政事务多,很长时间没来产科了。做全麻诱导时,他问我 thiopental 要推多少 - 他知道产妇中枢需要量少,加血浆蛋白低,用药量要少,但少多少他忘记了。后来我到一家新医院,当地主任是心血管麻醉专家。有一次因为处理产科麻醉事务时,问我刨宫产用什么药。人不可能什么都会,永远不忘,我并没有因为两个主任问了我一个基本问题,就失去了对他们的尊重。上周,我和一位住院医师在一起做脊柱全麻,我忘记了 propofol 对诱导电位图形的影响,这位住院医生马上有了回答。我想他也不会因为我忘了这个问题,就会失去对我的尊重。容易自满和鄙视同行的人,是很难通找到合适的工作伙伴的(请各位勿对号入座)。

8。病人和医生的诚信(有些事是各地体制环境不同,我这里只是介绍,不是指责):

病人来到医院,面对的是受过高等教育和漫长训练的医生,其中麻醉医生是手术有没有生命危险和有没有疼痛和知晓的关键人物,病人对麻醉医生说的话是当圣旨的。我们的义务是将麻醉的方式,所需要的操作,和各类麻醉的优点和风险,介绍给病人,然后提出合理方案,病人一般是会理解同意我们的方案。出现了意外情况,要和病人和家属说清楚,获得谅解。记得我在做住院医生时,主治是刚毕业的新手,周六遇见一位某种癌症胸段脊柱转移,脊柱外科和胸外科要行转移病灶切除。此手术估计范围极大,失血多,动静脉管,双腔插管,特殊体位都要使用,病人一般状况已经很差,但他和家属愿意冒险获得最后一次治疗的机会。我们对病人讲述了麻醉的风险,明确地告诉他,也许他不会醒过来。病人和家属都很理解我们,最后病人在 ICU ,直到去世,我们去探访过几次,家属一直都很感激。上周,我叫停一台手术:一位慢性阴道出血患者,由于特肥胖(400多磅),没有人能在门诊为这为患者检查。妇科医生要求在全麻和肌松下进行检查。早上住院医生告诉我说病人早上上车时有心慌胸痛症状,让我决定是否手术。我知道这类贫困患者,非急诊手术,要排很长时间才获得手术机会,况且妇科怀疑该患者是肿瘤,我是很想让手术进行下去,尽管由于她的体重和体型原因,心脏评估很不令人满意。我在自我介绍时,把这些想法告诉了病人,病人很感激,也愿意和我们同担风险。但随后我继续查看了新出来的胸片结果和当日氧饱和度,发现病人有缺氧,胸片有 infiltration 病灶,我想如果全麻,她很可能脱不了机。术后在 ICU ,呼吸机很难管理,加上感染因素,病人有可能死亡。我把这些想法告诉了妇科,他们非常理解,说他们是很想知道患者的诊断,为她做点什么,但也不希望让她冒不必要的风险。我后来向病人解释了我的思维经过,最后说,我很想帮你,但我也不希望看到你死亡,我们至少要把肺部病灶弄清楚。病人听了很泄气,但也很理解。回想我执业多年,自己本人和手下经管住院医,出现过多种并发症,如区域麻醉无效,角膜损伤,导管断裂,术中心跳骤停,术后负压肺水肿,每次都是和病人说清情况,说明原因,获得病人理解。


texasmousedoc edited on 2008-01-22 22:05

[ 本帖最后由 rextao 于 2009-4-7 14:37 编辑 ]

评分

1

查看全部评分

有奖活动:我为论坛出谋划策!! ←点击查看详情

126#
发表于 2009-4-8 20:57:23 | 只看该作者
版主,我觉得你应该说说你自己所在医院的特色。华西的魔鬼式的训练都训练了什么啊,让我们也参考参考。

有奖活动:我为论坛出谋划策!! ←点击查看详情

127#
发表于 2009-4-8 21:01:02 | 只看该作者

回复 123# rextao 的帖子

这不是舒芬太尼的说明书吗?靶控输注怎么用好像没有,现在做心脏手术基本都是用它靶控(成人)。

有奖活动:我为论坛出谋划策!! ←点击查看详情

128#
发表于 2009-4-8 21:41:11 | 只看该作者

回复 82# rextao 的帖子

重度主动脉关闭不全麻醉管理的目标是不是心率可以相对快一点,血压可以相对低一点?小儿高钾的处理是不是利尿,胰岛素和钙剂呢。小儿心衰怎么判断呢?左心衰是不是肺罗音,右心衰应该是肝大和眼睑肿胀。

有奖活动:我为论坛出谋划策!! ←点击查看详情

129#
发表于 2009-4-18 00:02:45 | 只看该作者

回复 1# rextao 的帖子

华西 华西
多少青年麻友的精神家园呐!

友情提示:转载请注意注明作者和出处!!

130#
 楼主| 发表于 2009-4-18 14:00:34 | 只看该作者

Intradermal Injection of Capsaicin in Humans

The Journal of Neuroscience, November 1, 1998, 18(21):8947-8959


Intradermal Injection of Capsaicin in Humans Produces Degeneration and Subsequent Reinnervation of Epidermal Nerve Fibers: Correlation with Sensory Function
Donald A. Simone1, 2, Maria Nolano3, Timothy Johnson4, Gwen Wendelschafer-Crabb4, and William R. Kennedy4
Departments of 1 Psychiatry, 2 Preventive Sciences, and 4 Neurology, University of Minnesota, Minneapolis, Minnesota 55455, and 3 Salvatore Maugeri Foundation, Campoli M.T. (BN), Italy

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References  

The ability of capsaicin to excite and subsequently to desensitize a select group of small sensory neurons has made it a useful tool to study their function. For this reason, application of capsaicin to the skin has been used for a variety of painful syndromes. We examined whether intradermal injection of capsaicin produced morphological changes in cutaneous nerve fibers that would account for its analgesic properties by comparing cutaneous innervation in capsaicin-treated skin with psychophysical measures of sensation. At various times after capsaicin injection, nerve fibers were visualized immunohistochemically in skin biopsies and were quantified. In normal skin the epidermis is heavily innervated by nerve fibers immunoreactive for protein gene product (PGP) 9.5, whereas fibers immunoreactive for substance P (SP) and calcitonin gene-related peptide (CGRP) are typically associated with blood vessels. There was nearly complete degeneration of epidermal nerve fibers and the subepidermal neural plexus in capsaicin-treated skin, as indicated by the loss of immunoreactivity for PGP 9.5 and CGRP. The effect of capsaicin on dermal nerve fibers immunoreactive for SP was less obvious. Capsaicin decreased sensitivity to pain produced by sharp mechanical stimuli and nearly eliminated heat-evoked pain within the injected area. Limited reinnervation of the epidermis and partial return of sensation occurred 3 weeks after treatment; reinnervation of the epidermis was ~25% of normal, and sensation improved to 50-75% of normal. These data show that sensory dysfunction after capsaicin application to the skin results from rapid degeneration of intracutaneous nerve fibers.

Key words: pain; analgesia; protein gene product 9.5; intracutaneous nerves; immunohistochemistry; confocal microscopy

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References  
Capsaicin, the active pungent ingredient in hot peppers, is a unique tool used to study the functions of a subset of sensory neurons, including nociceptive neurons. Early studies focused on the neurotoxic actions of capsaicin applied systemically in high doses to neonatal or adult rats (for review, see Nagy, 1982; Fitzgerald, 1983; Russell and Burchiel, 1984; Buck and Burks, 1986; Holzer, 1991). It was found that capsaicin destroys a subset of small diameter primary afferent fibers and their cell bodies.

Topical application of capsaicin evokes burning pain, neurogenic inflammation (vasodilatation and plasma extravasation), and hyperalgesia to heat and mechanical stimuli (Szolcsányi, 1977; Carpenter and Lynn, 1981; Culp et al., 1989; Simone and Ochoa, 1991). After repeated applications, the treated area becomes less sensitive to pain. This desensitizing action has made capsaicin attractive for use as a peripherally acting analgesic for chronic painful syndromes (Capsaicin Study Group, 1991; Fusco and Giacovazzo, 1997).

Intradermal injection of capsaicin quickly deposits a quantified amount directly into human skin. This produces a sensation of intense burning pain and hyperalgesia to heat and mechanical stimuli (Simone et al., 1987, 1989; LaMotte et al., 1991, 1992), followed by a rapid desensitization characterized by diminished pain sensation at the site of application (LaMotte et al., 1991). Electrophysiological studies have shown that shortly after intradermal injection of capsaicin, C-fiber polymodal nociceptors can become insensitive to mechanical and heat stimuli (Baumann et al., 1991). Furthermore, this effect of capsaicin is well localized to the injection site because only the portion of the receptive field exposed to capsaicin becomes desensitized. Thus, diminished pain sensation at the site of capsaicin injection is attributed to desensitization of nociceptors.

The mechanisms underlying rapid desensitization and hypalgesia after local capsaicin application in humans are unclear. Desensitization of capsaicin-sensitive afferent fibers involves a continuum of physiological and morphological changes that are dependent on capsaicin dose and route of administration. The effects of capsaicin on neural function, whether applied systemically or locally, have been categorized into various stages in animal studies and range from conduction block with reversible ultrastructural changes in peripheral nociceptive endings to irreversible degeneration of nociceptive neurons and their processes (Szolcsányi, 1993). For example, although systemic application of high doses of capsaicin destroys certain sensory neurons, capsaicin applied to the peripheral nerve endings in the cornea produces swelling of mitochondria and a reduction in the number of microvesicles in unmyelinated nerve endings without evidence of axonal degeneration (Szolcsányi et al., 1975). Morphological correlates of functional desensitization after capsaicin application to skin are unknown. Although topical capsaicin decreased the number of nerve fibers in the epidermis as observed in a blister roof (Reilly et al., 1997), this was not verified by skin biopsy or sensory testing. Therefore, in this correlative study in humans, psychophysical measures of cutaneous sensation and immunohistochemical techniques were used to determine whether the hypalgesia after intradermal injection of capsaicin could be attributed to morphological changes in epidermal nerve fibers (ENFs).

A preliminary report has been published previously (Simone et al., 1996).

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References  
Subjects. Eight subjects (six male and two female) ranging in age from 24 to 69 years participated. Each subject provided informed consent to a protocol that was approved by the Institutional Review Board Human Subjects Committee of the University of Minnesota.

Intradermal injection of capsaicin. Capsaicin was dissolved in a vehicle containing 7.5% Tween 80 in saline as described previously (Simone et al., 1987, 1989; LaMotte et al., 1991). All injections were given into test areas (5 mm in diameter) marked on the lateral aspect of the upper arm. Capsaicin doses of either 0.2, 2, or 20 µg in a volume of 20 µl or an equal amount of the vehicle was injected into each site using a 0.5 ml insulin syringe. A maximum of seven injections were given into each shoulder. Before each injection, the skin was anesthetized with an intradermal injection of 1% lidocaine (0.3-0.5 ml).

Psychophysical measures of cutaneous sensation. Heat pain, pricking pain, cold sensation, and tactile threshold were evaluated within each 5-mm-diameter test site. Thermal stimuli of 5 sec duration were applied via a 2-mm-diameter contact probe maintained at 53°C for heat pain or 1°C for cold sensation. Subjects judged the magnitude of heat pain and the magnitude of cold sensation using a visual analog scale ranging from 0 (no pain) to 10 (most severe pain imaginable). Heat and cold stimuli were each applied five times, and the mean magnitude of pain and cold sensation was determined. Pricking pain was evoked by a sharp probe (50-µm-diameter tip) attached to a nylon monofilament with a bending force of 95 mN. This probe did not penetrate the skin. The stimulus was applied 10 times, each for a duration of 1-2 sec. The proportion of stimulus presentations that evoked pain, as well as the magnitude of pain, was recorded. Tactile threshold (in mN) was determined by the use of calibrated Semmes-Weinstein monofilaments. Threshold was defined as the smallest monofilament that could be perceived at least 50% of the time. Individual monofilaments were applied 10 times beginning with a suprathreshold stimulus. All sensory tests were performed at each test site before and at various times after injection.

Skin biopsy and immunohistochemistry. Skin biopsies were obtained from vehicle- and capsaicin-treated sites and occasionally from untreated skin. After the skin was anesthetized by intradermal injection of 1% xylocaine (Astra, Westborough, MA), the biopsy was made with a 3 mm punch tool (Acupunch; Acuderm, Fort Lauderdale, FL) and processed as described previously (Kennedy et al., 1996). Briefly, biopsies were fixed in Zamboni's solution, cryoprotected, and sectioned with a freezing sliding microtome (Leica, Nussloch, Germany). Diluent and washing solutions comprised 1% normal donkey serum (Jackson ImmunoResearch, West Grove, PA) in 0.1 M PBS with 0.3% Triton X-100 (Sigma, St. Louis, MO). Floating sections were blocked with 5% normal donkey serum in the diluent solution. Nerve and tissue antigens were localized using primary antibodies to protein gene product (PGP) 9.5 (1:800; Ultraclone, Isle of Wight, England), substance P (SP) (1:1000; Incstar, Stillwater, MN), calcitonin gene-related peptide (CGRP) (1:1000; Amersham, Arlington Heights, IL) and type IV collagen (Chemicon, Temecula, CA), each diluted in PBS-Triton X-100-NGS. Nonimmune serum was used for negative controls. Secondary antibodies specific to the IgG species used as a primary antibody and labeled with cyanine dye fluorophores 3.18 and 5.18 (Jackson ImmunoResearch) were used to locate two antigens in each section. After immunohistochemical processing, sections were adhered to coverslips with agar, dehydrated via an alcohol series, cleared with methyl salicylate, and mounted in DPX (Fluka BioChemika, Ronkonkoma, NY).

Imaging and quantification of ENFs. Images of sections that were double stained with PGP 9.5 and type IV collagen were collected with a laser-scanning confocal microscope (Bio-Rad, Hercules, CA) with a Nikon 20× planapochromate objective (numerical aperture, 0.75) and appropriate filters. Each image set comprised a z-series that was acquired in 2 µm increments throughout the thickness of the section.

Quantitative analyses of ENFs were performed as described previously (Kennedy et al., 1996). Briefly, z-series image stacks of PGP 9.5-immunostained ENFs were acquired from the biopsy sections with the confocal microscope, and the images were analyzed with Neurolucida software (MicroBrightField, Colchester, VT) by tracing nerve fibers in three dimensions. Individual ENFs are counted as they pass through the basement membrane. Branching occurring within the epidermis did not increase the number of ENFs counted. Epidermal nerve counts of PGP 9.5-immunoreactive fibers were standardized for section thickness (30 µm) and expressed as the number of fibers per millimeter of epidermis.

The subepidermal neural plexus and SP- and CGRP-immunoreactive fibers were examined qualitatively by visual inspection with the use of fluorescence microscopy.

Data analyses. ENFs were counted, quantified, and compared with the number of ENFs per millimeter length in normal epidermis. A one-way ANOVA was used to compare the number of ENFs present 3 d after intradermal injection of vehicle and of 0.2, 2, and 20 µg doses of capsaicin. The innervation of epidermis before and between 1 and 4 weeks after an intradermal injection of 20 µg was assessed by repeated-measures ANOVA. Comparisons were made between the number of ENFs in capsaicin-treated skin, vehicle-treated skin, and normal untreated skin.

The effect of capsaicin on psychophysical measures of heat pain sensation, cold sensation, and tactile sensation and on the proportion of sharp stimuli perceived as painful was assessed using ANOVAs with repeated measures. Separate analyses were used to examine the effect of capsaicin dose on the various sensory modalities and to evaluate changes in sensation over a 4 week time period after a single injection of 20 µg of capsaicin.

Experimental design. To determine the effect of graded doses of capsaicin on the sensation and morphology of ENFs, we gave each of five subjects one set of four intradermal injections on each upper arm. A set of injections consisted of capsaicin doses of 0.2, 2, and 20 µg and the vehicle. Sensation was assessed and skin biopsy was performed at each injection site after 24 hr for one set of injections and after 72 hr for the other set.

In a separate experiment, we determined the time course and extent of reinnervation and whether reinnervation is accompanied by the return of normal pain sensation. Five subjects were given four intradermal injections of 20 µg of capsaicin into the upper arm. Evoked sensation and cutaneous innervation were assessed at each injection site at 1, 2, 3, or 4 weeks after injection. Three subjects received one additional injection of capsaicin, and measurements were also made at 6 weeks after injection.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References  
Effect of capsaicin on the number of ENFs and cutaneous sensation: dose-response relationships

In vehicle-treated skin, like normal untreated skin, PGP 9.5-immunoreactive nerve fibers are abundant in the subepidermal neural plexus, which lies just below the basement membrane (Fig. 1, Veh). The epidermis is richly innervated by fibers that originate in the subepidermal plexus and project up through the basement membrane and terminate in the epidermis. It is likely that all nerve fibers have been visualized because PGP 9.5-immunoreactive axons are greater in number and density and the staining is stronger than that seen with antisera to other neural markers (Karanth et al., 1991). It has been shown previously that nerve fibers extending into the epidermis are unmyelinated (Ochoa, 1984; Wang et al., 1990; Kennedy and Wendelschafer-Crabb, 1993).



View larger version (81K):
[in this window]
[in a new window]
   Figure 1.   Confocal images showing innervation of epidermis and superficial dermis for one subject at 72 hr after a single injection of vehicle (Veh) or capsaicin doses of 0.2, 2.0, or 20 µg. Nerve fibers (N) immunoreactive for PGP 9.5 appear yellow-green; the basement membrane (B) and vessels (V) appear red. Scale bars, 100 µm.




Capsaicin produced a rapid, dose-dependent degeneration of intracutaneous nerve fibers and a dramatic decrease in the sensation of pain produced by heat and mechanical stimuli. All three doses of capsaicin caused a significant reduction in the mean number of ENFs as compared with that in vehicle-treated skin (p < 0.05). Although nerve degeneration was evident at 24 hr after injection, the magnitude and spatial extent of fiber loss were more pronounced at 72 hr after injection. An example of nerve degeneration after capsaicin injection is provided in Figure 1, which shows confocal images of skin biopsies for one subject with typical neural degeneration observed at 72 hr after injection. After the lowest dose of capsaicin, loss of PGP 9.5-immunoreactive nerve fibers was restricted primarily to fibers located in the epidermis, with little to moderate disruption of nerve fibers in the subepidermal neural plexus. Higher doses of capsaicin resulted in complete loss of PGP 9.5-immunoreactive ENFs plus various degrees of disruption or complete loss of the subepidermal nerve plexus.

Nerve fibers immunoreactive for CGRP and SP are sparsely distributed throughout the papillary dermis where they are typically associated with capillary loops. CGRP-immunoreactive nerve fibers occasionally penetrate the epidermis, whereas SP-immunoreactive fibers are sparse in the subepidermal neural plexus and rarely enter the epidermis. Complete loss of CGRP- immunoreactive fibers was also observed 72 hr after capsaicin injection. The effect of capsaicin on SP-immunoreactive nerve fibers was difficult to assess because very few fibers are normally found in the superficial dermis, and after capsaicin a few SP-immunoreactive nerve fibers were found in some subjects, whereas no SP-immunoreactive fibers were found in other subjects.

The relationship between capsaicin dose, somatic sensation, and the number of PGP 9.5-immunoreactive ENFs at 72 hr after injection is summarized for all five subjects in Figure 2. The mean (± SEM) decrease in the number of ENFs per length (in millimeters) of epidermis at 72 hr after injection of 0.2, 2, and 20 &micro;g of capsaicin was 43.5 ± 13.2, 98.7 ± 1.33, and 99.9 ± 0.99%, respectively, compared with that in vehicle-treated skin. The decrease in the number of ENFs was associated with diminished pain sensation. One-way ANOVAs revealed that capsaicin decreased the magnitude of heat pain sensation (p < 0.001) and the detection of sharp pain sensation (p < 0.001). However, heat pain sensation was more sensitive to capsaicin treatment than was mechanical pain sensation. The magnitude of heat pain sensation decreased significantly after injection of 2 and 20 &micro;g of capsaicin (p < 0.05), whereas the proportion of sharp mechanical stimuli perceived as painful decreased significantly after the 20 &micro;g dose (p < 0.05). Tactile threshold was not altered significantly after capsaicin injection, but the effect of capsaicin on this measure varied considerably between subjects. Although the magnitude of cold sensation did not decrease significantly, the subjective magnitude of cold decreased >50% in two of five subjects after the 2 &micro;g dose and in three of five subjects after the 20 &micro;g dose. The remaining subjects experienced a lesser decrement in cold sensation or no change at all. Injection of the vehicle did not produce significant changes in any evoked sensations or in innervation density as compared with that in normal untreated skin.



View larger version (15K):
[in this window]
[in a new window]
   Figure 2.   Somatic sensation and the number of ENFs for all five subjects at 72 hr after injection of capsaicin. Data are expressed as the mean (± SEM) percent change from the data for vehicle-treated skin. For heat pain and cold sensation, data represent the change in the magnitude of sensation. Mechanical pain sensation is represented as the change in the proportion of stimuli perceived as painful.




Reinnervation of the epidermis and restoration of sensory function

To determine the extent to which ENFs regenerated after capsaicin as well as the time course of epidermal reinnervation, we performed skin biopsies and sensory tests at capsaicin injection sites 1-4 (n = 5) or 6 (n = 3) weeks after the injection. A one-way ANOVA indicated a significant decrease in ENFs after capsaicin (p < 0.001) compared with that in normal skin. All subjects exhibited denervation in capsaicin-treated skin during the first 2 weeks after injection, and ENFs were rarely observed. Similarly, nerve fibers in the subepidermal neural plexus were also sparse during this time period. Reinnervation of the epidermis by ENFs began during the third and fourth weeks after the capsaicin injection and was characterized by the return of an intact subepidermal neural plexus and the reappearance of sparse nerve fibers in the epidermis. However, the innervation of epidermis during this time was still dramatically impaired, and the number of ENFs per length (in millimeters) of epidermis ranged from only 12 to 29% of that in normal skin. Figure 3 shows confocal images of biopsy sections stained for PGP 9.5 immunoreactivity in normal untreated skin and in skin at 1, 2, and 4 weeks after capsaicin treatment for one subject. For this subject, who exhibited the most reinnervation of all subjects tested, innervation of the epidermis did not improve further between 4 and 6 weeks (we did not examine at any later time).



View larger version (102K):
[in this window]
[in a new window]
   Figure 3.   Confocal images showing denervation and reinnervation of epidermis and superficial dermis by PGP 9.5-immunoreactive nerve fibers for one subject. Biopsies were taken from capsaicin-treated (20 &micro;g) skin at 1, 2, and 4 weeks after injection and from normal untreated skin. The appearance of nerve fibers immunoreactive for PGP 9.5 is the same as that described in Figure 1. Scale bars, 100 &micro;m.




Nerve fibers immunoreactive for CGRP also reappeared 3-4 weeks after capsaicin (Fig. 4). These CGRP-immunoreactive nerve fibers were never observed in the epidermis or superficial dermis 1 week after capsaicin. However, they were found in the dermis, but not the epidermis, 4 weeks after injection of capsaicin. Although quantitative measures of the number of CGRP-immunoreactive fibers were not made, the number of fibers present at 4 weeks after capsaicin appeared to be less than normal, as with PGP 9.5-immunoreactive fibers.



View larger version (131K):
[in this window]
[in a new window]
   Figure 4.   Confocal images of skin biopsies from one subject showing nerve fibers immunoreactive for CGRP and SP in normal skin and skin at 1 and 4 weeks after capsaicin injection. Right, CGRP-immunoreactive fibers were completely absent 1 week after capsaicin injection and reappeared 4 weeks after injection (arrows). Left, There was not a complete loss of SP-immunoreactive fibers at 1 week after capsaicin injection, and one fiber can be seen oriented horizontally below the basement membrane (arrow). At 4 weeks after capsaicin injection, fibers were occasionally found deep in the dermis (arrow) and oriented vertically toward the basement membrane. Scale bars, 100 &micro;m.




The extent of reinnervation of SP-immunoreactive nerve fibers was difficult to assess because of the small number of fibers normally observed in the superficial dermis and epidermis. A few nerve fibers were found in at least some of the subjects at all times examined after capsaicin. These fibers were observed only in the dermis, and the number of these fibers found was similar to that in normal skin.

Gradual reinnervation of the epidermis coincided with the gradual restoration of evoked pain sensation. This is illustrated in Figure 5 that shows the mean change in the number of PGP 9.5-immunoreactive ENFs and the mean change in sensation for all subjects. The magnitude of heat pain sensation and the percent of mechanical stimuli perceived as painful decreased significantly after capsaicin (p < 0.001). During the first 2 weeks after capsaicin injection, heat pain sensation was nearly eliminated, and subjects exhibited an ~65% decrease in the proportion of sharp mechanical stimuli perceived as painful. However, the decrease in mechanically evoked pain sensation was variable compared with the changes in heat pain sensation. For example, during the first 2 weeks after capsaicin, three of the six subjects did not perceive sharp pain, whereas the detection of sharp pain was not altered in one subject. Although there were no significant alterations in the sensation of cold during the first 2 weeks after capsaicin, all but one subject exhibited at least a 16% decrease in the magnitude of cold sensation. Similarly, there was no significant change in tactile threshold during this time. Tactile thresholds were increased in three of the six subjects and were unchanged in the remaining three subjects.



View larger version (17K):
[in this window]
[in a new window]
   Figure 5.   The mean (± SEM) change in sensation and in the number of ENFs for all subjects through 1-6 weeks after injection of 20 &micro;g of capsaicin. Data are presented as the percent change from normal untreated skin.




At 3 and 4 weeks after capsaicin, detection of heat pain and of pricking pain sensation had improved and was consistent with the onset of reinnervation of the epidermis. There remained a 37 ± 19.9% decrease in heat pain at 4 weeks after capsaicin as compared with that in normal skin. Similarly, the sensation of pricking pain also improved but was more variable than was the pain sensation evoked by heat.

Localization of capsaicin-evoked nerve degeneration

To determine the extent to which capsaicin diffused from the injection site to cause degeneration of nerve fibers adjacent to the injection site, we made one biopsy 72 hr after injection of 20 &micro;g of capsaicin that included part of the injection site (as defined by the appearance of the bleb) and adjacent skin. A confocal image of this biopsy is provided in Figure 6. It can be seen that the left portion of the biopsied skin does not contain ENFs, whereas ENFs are clearly seen in the right portion. The right portion of the biopsy, which has a normal appearance and number of ENFs, was ~1-2 mm from the edge of the capsaicin injection. This demonstrates that capsaicin diffuses minimally from the injection site and that nerve degeneration is restricted to the capsaicin-treated area.



View larger version (30K):
[in this window]
[in a new window]
   Figure 6.   The localization of degeneration of ENFs after an intradermal injection of 20 &micro;g of capsaicin as shown by confocal images of skin biopsy from one subject. Top, Montage of confocal images that span across the skin biopsy. Abundant ENFs are seen only at the far right portion of the biopsy, which was located outside the capsaicin injection site and presumably not exposed to the neurotoxin. Bottom, The two opposite ends of the skin biopsy, outlined by the squares in the top image, shown at greater magnification to illustrate differences in epidermal innervation.




    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References  
The present findings demonstrate that intradermal injection of capsaicin produces rapid degeneration of nerve fibers in the epidermis and superficial dermis. This phenomenon is local in that it occurred only at the site of injection and presumably only to those nerve fibers that came in contact with capsaicin. We used loss of immunoreactivity for PGP 9.5 as evidence of degeneration. It could be argued that capsaicin interferes with expression of PGP 9.5 without producing nerve fiber destruction. However, we believe the initial loss and subsequent reappearance of immunoreactivity for PGP 9.5 coincides with degeneration and subsequent regeneration for the following reasons. First, capsaicin produced a clear disruption of the subepidermal neural plexus within 3 d after intradermal injection, followed by a gradual loss within the next 2 weeks. Second, loss of immunoreactivity also occurred for the neuropeptide CGRP, and there appeared to be a decrease in the number of SP-immunoreactive fibers. Third, the reappearance of immunoreactivity for PGP 9.5 was gradual and consistent with the gradual regeneration of the subepidermal neural plexus and reinnervation of the epidermis. Fourth, the number of PGP 9.5-immunoreactive fibers that reappeared was less than that in normal skin, even at 4 and 6 weeks after capsaicin injection. Fifth, the loss and subsequent reappearance of immunoreactivity for PGP 9.5 correlated well with the loss and recovery of somatic sensation. The combined disappearance of immunoreactivity for a cytoplasmic protein and two neuropeptides and the associated decrement in sensation strongly suggest that intracutaneous nerve fibers degenerated.

Degeneration of intradermal and epidermal nerve fibers by locally applied capsaicin raises several important issues regarding (1) the mechanisms of hypalgesia produced by capsaicin, (2) the mechanisms by which capsaicin produces local degeneration of nerve fibers, and (3) the function of epidermal nerve fibers in sensation, which are each discussed below. It is noteworthy that capsaicin produced degeneration of ENFs in the presence of local anesthesia. This suggests that degeneration produced by capsaicin is not dependent on excitation and generation of action potentials.

Hypalgesia and degeneration after capsaicin

Many studies have documented that application of capsaicin to the skin initially produces pain and hyperalgesia followed by diminished pain sensation, referred to as functional desensitization. The peripheral neural mechanisms that contribute to the positive sensory phenomena of pain and hyperalgesia produced by intradermal injection of capsaicin include excitation and sensitization of C polymodal nociceptors, whereas the neural mechanisms underlying functional desensitization subsequent to capsaicin treatment are unclear. One possibility is that capsaicin depletes C-fibers of neuropeptides, such as SP and CGRP, resulting in desensitization of nociceptors. Capsaicin has been shown to release these and other peptides from the peripheral endings of primary afferent fibers (Holzer, 1988; Maggi and Meli, 1988; Saria et al., 1988). Recent electrophysiological studies, however, suggest that initial desensitization and hypalgesia are related to the effects of capsaicin on neuronal ion channels. It has been found that capsaicin initially excites nociceptors by interacting with a specific receptor (Szallasi and Blumberg, 1990a,b; Caterina et al., 1997) to decrease the input resistance (Heyman and Rang, 1985), to evoke an inward current (Bevan and Docherty, 1993), and to open nonselective cation channels (Wood et al., 1988; Bleakman et al., 1990; Docherty et al., 1991). This is followed by the inactivation of voltage-gated ion channels that prevents the generation of action potentials and may account for short-lasting desensitization and hypalgesia. It is therefore possible that capsaicin interferes with the generation of action potentials by causing ultrastructural damage (e.g., mitochondrial swelling) to nociceptive endings as a result of prolonged opening of cation channels. Although the mechanisms described above may account for initial desensitization and corresponding hypalgesia, it is unlikely that they account for the long-lasting hypalgesia observed in the present study. Rather, our findings demonstrate that hypalgesia results from the loss of nerve fibers. This is the first study to examine the morphology of intradermal and ENFs located at the site of capsaicin injection. Our results are compatible with a previous study in which repeated application of topical capsaicin to the rat hindpaw produced no evidence of either nerve damage in the sciatic nerve (proximal to capsaicin application) or neuron loss in the dorsal root ganglion (DRG) (McMahon et al., 1991). Although topical capsaicin did not produce remote degeneration of nerve fibers in the nerve trunk or of sensory neurons in the DRG, it was not determined whether capsaicin produced degeneration locally at the site of application. It has been shown, however, that systemic administration of capsaicin caused some degeneration of the subepidermal neural plexus (Chung et al., 1990), demonstrating susceptibility of intracutaneous nerve fibers to the neurotoxic actions of capsaicin. Also, local application of capsaicin has been shown to cause degeneration of DRG neurons and axons (Handwerker et al., 1984; Marsh et al., 1987; Pini et al., 1990). As illustrated in the present study, degeneration occurred only at the site of capsaicin application and in those fibers exposed to the neurotoxin. Moreover, degeneration was progressive in that only ENFs were affected at 24 hr after capsaicin, whereas degeneration included the subepidermal neural plexus within 1 week and the dermal CGRP- and SP-immunoreactive nerve fibers. This was illustrated more clearly in a parallel study (Nolano et al., 1996) in which repeated topical application of capsaicin produced gradual degeneration of nerve fibers in the epidermis. Recently, Reilly et al. (1997) confirmed the use of the blister technique to show degeneration of ENFs by capsaicin. Thus, capsaicin seems to produce a gradual but limited dying back of fibers from the nerve endings in the epidermis. This pattern of degeneration is common with various types of clinical neuropathies, such as diabetic neuropathy (Kennedy et al., 1996) and neuropathy associated with human immunodeficiency virus injection (McCarthy et al., 1995).

Functions of epidermal nerve fibers

The present findings provide new information about the function of ENFs. Because loss of ENFs correlated primarily with diminished pain sensation, we believe that many of the ENFs are nociceptors. Furthermore, many are likely to be polymodal nociceptors because pain evoked by heat and mechanical stimuli was depressed. However, an interesting paradox is that cold and tactile sensitivities were not altered significantly, although virtually all fibers in the superficial skin were absent. Although the probe used for cold sensation was small and maintained at very low temperature, it evoked cold sensation without pain. This suggests that cold-specific receptors normally sensitive to innocuous cold temperatures were excited. The finding that cold and tactile sensations were not altered by capsaicin is in agreement with electrophysiological studies showing that evoked responses of low threshold receptors were not altered after intradermal injection of capsaicin (Baumann et al., 1991). It is likely that those sensations arose from activation of receptors located deep in the dermis or just adjacent to the capsaicin injection where innervation is normal. Similarly, deep nociceptors or activated proximal segments of ENFs are likely to account for the residual pricking pain sensation that persisted after capsaicin treatment.

There seemed to be a mismatch in the relationship between the number of regenerated ENFs and evoked sensation. During reinnervation when there were relatively few fibers in the epidermis, there was a striking return of heat and sharp pain sensation. For example, at 3 weeks after capsaicin injection, the mean magnitude of heat pain and sharp pain sensation was 61 and 77%, respectively, of that obtained in normal skin. At this time, however, epidermal reinnervation was only ~17% of normal. Two possibilities might account for the apparent mismatch between the magnitude of sensation and the number of epidermal nerve fibers. One is that relatively few epidermal nerve fibers are needed for pain detection. This is supported by microneurography studies in humans that suggest activation of a small number of nociceptive primary afferent fibers evoke clear pain sensation (Ochoa and Torebj&ouml;rk, 1989). If this is true, sensory testing by conventional methods may not be sensitive enough to detect neuropathy in the early stages of degeneration. A second possibility is that the subepidermal neural plexus and receptors located on these fibers contribute to evoked sensation. Indeed at 3 weeks or less after capsaicin treatment, the subepidermal neural plexus appeared to have returned to normal, on visual inspection, with respect to its density and continuity.

Conclusions

The present study demonstrates that the hypalgesia after application of capsaicin to the skin results from degeneration of ENFs. This finding has important clinical implications because topical capsaicin has been used for a variety of painful syndromes, including diabetic neuropathy. Because we have shown that degeneration of ENFs also occurs after topical capsaicin, although the degeneration has a slower onset and is not as severe as that produced by intradermal injection (Nolano et al., 1996), it is debatable whether capsaicin should be used in syndromes in which there is ongoing nerve pathology and nerve regeneration is necessary to preserve or restore detection of noxious stimuli. In this regard, the capsaicin model may be useful to study mechanisms of regeneration of intracutaneous nerve fibers and to assess the effects of neurotrophins and other pharmacological agents in correlative morphological and psychophysical studies.

    FOOTNOTES

Received May 13, 1998; revised Aug. 12, 1998; accepted Aug. 13, 1998.

This work was supported in part by National Institutes of Health Grants NS31223 (D.A.S.) and NS31397 (W.R.K.) and by a grant from Toray Industries Inc. (W.R.K.). We thank Dr. Paul Thuras for assistance with statistical analyses.

Correspondence should be addressed to Dr. Donald A. Simone, Department of Psychiatry, University of Minnesota, 420 Delaware Street SE, Box 392, Minneapolis, MN 55455.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References  

Baumann TK, Simone DA, Shain CN, LaMotte RH (1991) Neurogenic hyperalgesia: the search for the primary afferent nerve fibers that contribute to capsaicin-induced pain and hyperalgesia. J Neurophysiol 66:212-227[Abstract/Free Full Text].
Bevan SJ, Docherty RJ (1993) Cellular mechanisms of the action of capsaicin. In: Capsaicin in the study of pain (Wood J, ed), pp 27-44. London: Academic.
Bleakman D, Brorson JR, Miller RJ (1990) The effect of capsaicin on voltage-gated calcium currents and calcium signals in cultured dorsal root ganglion cells. Br J Pharmacol 101:423-431[ISI][Medline].
Buck SH, Burks TF (1986) The neuropharmacology of capsaicin: review of some recent observations. Pharmacol Rev 38:179-226[ISI][Medline].
Capsaicin Study Group (1991) Arch Intern Med 151:2225-2229[Abstract/Free Full Text].
Carpenter SE, Lynn B (1981) Vascular and sensory responses of human skin to mild injury after topical treatment with capsaicin. Br J Pharmacol 73:755-759[ISI][Medline].
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816-824[ISI][Medline].
Chung K, Klein CM, Coggeshall RE (1990) The receptive part of the primary afferent axon is most vulnerable to systemic capsaicin in adult rats. Brain Res 511:222-226[ISI][Medline].
Culp WJ, Ochoa JL, Cline M, Dotson R (1989) Heat and mechanical hyperalgesia induced by capsaicin. Cross modality threshold modulation in human C nociceptors. Brain 112:1317-1331[Abstract/Free Full Text].
Docherty RJ, Robertson B, Bevan S (1991) Capsaicin causes prolonged inhibition of voltage-activated calcium currents in adult rat dorsal root ganglion neurons in culture. Neuroscience 40:513-521[ISI][Medline].
Fitzgerald M (1983) Capsaicin and sensory neuronesa review. Pain 15:109-130[ISI][Medline].
Fusco BM, Giacovazzo M (1997) Peppers and pain. The promise of capsaicin. Drugs 53:909-914[ISI][Medline].
Handwerker HO, Holzer-Petsche U, Heym C, Welk E (1984) C-fibre functions after topical application of capsaicin to a peripheral nerve and after neonatal capsaicin treatment. In: Antidromic vasodilatation and neurogenic inflammation (Chahl LA, Szolcsányi J, Lembeck F, eds), pp 57-78. Budapest: Akadémiai Kiadó.
Heyman I, Rang HP (1985) Depolarizing responses to capsaicin in a subpopulation of dorsal root ganglion cells. Neurosci Lett 56:69-75[ISI][Medline].
Holzer P (1988) Local effector functions of capsaicin-sensitive sensory nerve endings: involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience 24:739-768[ISI][Medline].
Holzer P (1991) Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43:143-201[ISI][Medline].
Karanth SS, Pringall DR, Kuhn DM, Levene MM, Polak M (1991) An immunocytochemical study of cutaneous innervation and the distribution of neuropeptides and protein gene product 9.5 in man and commonly employed laboratory animals. Am J Anat 191:369-383[ISI][Medline].
Kennedy WR, Wendelschafer-Crabb G (1993) The innervation of the human epidermis. J Neurol Sci 115:184-190[ISI][Medline].
Kennedy WR, Wendelschafer-Crabb G, Johnson T (1996) Quantitation of epidermal nerves in diabetic neuropathy. Neurology 47:1042-1048[Abstract/Free Full Text].
LaMotte RH, Shain CN, Simone DA, Tsai E-F (1991) Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms. J Neurophysiol 66:190-211[Abstract/Free Full Text].
LaMotte RH, Lundberg LER, Torebj&ouml;rk HE (1992) Pain, hyperalgesia and activity in nociceptive C units after intradermal injection of capsaicin. J Physiol (Lond) 448:749-764[Abstract/Free Full Text].
Maggi CA, Meli A (1988) The sensory-efferent function of capsaicin-sensitive sensory neurons. Gen Pharmacol 19:1-43[ISI][Medline].
Marsh SJ, Stansfeld CE, Brown DA, Davey R, McCarthy D (1987) The mechanism of action of capsaicin on sensory C-type neurons and their axons in vitro. Neuroscience 23:275-290[ISI][Medline].
McCarthy BG, Hsieh S-T, Stocks A, Hauer P, Macko C, Cornblath DR, Griffin JW, McArthur JC (1995) Cutaneous innervation in sensory neuropathies: evaluation by skin biopsy. Neurology 45:1848-1855[Abstract/Free Full Text].
McMahon SB, Lewin G, Bloom SR (1991) The consequences of long-term topical capsaicin application in the rat. Pain 44:301-310[ISI][Medline].
Nagy JI (1982) Capsaicin: a chemical probe for sensory neuron mechanisms. In: Handbook of psychopharmacology, Vol 15 (Iversen LL, Iversen SD, Snyder SH, eds), pp 185-235. New York: Plenum.
Nolano M, Simone DA, Wendelschafer-Crabb G, Kennedy WR (1996) Decreased sensation and loss of epidermal nerve fibers following repeated topical application of capsaicin in humans. Soc Neurosci Abstr 22:1802.
Ochoa JL (1984) Peripheral unmyelinated units in man: structure, function, disorder, and role in sensation. In: Advances in pain research and therapy, Vol 6 (Kruger L, Liebeskind JC, eds), pp 53-68. New York: Raven.
Ochoa JL, Torebj&ouml;rk H (1989) Sensations evoked by intraneural microstimulation of C nociceptor fibres in human skin nerves. J Physiol (Lond) 415:583-599[Abstract/Free Full Text].
Pini A, Baranowski R, Lynn B (1990) Long-term reduction in the number of C-fibre nociceptors following capsaicin treatment of a cutaneous nerve in adult rats. Eur J Neurosci 2:89-97[ISI][Medline].
Reilly DM, Ferdinando D, Johnston C, Shaw C, Buchanan KD, Green MR (1997) The epidermal nerve fibre network: characterization of nerve fibres in human skin by confocal microscopy and assessment of racial variations. Br J Dermatol 137:163-170[ISI][Medline].
Russell LC, Burchiel KJ (1984) Neurophysiological effects of capsaicin. Brain Res Rev 8:165-176.
Saria A, Martling CR, Yan Z, Theodorsson-Norheim E, Gamse R, Lundberg JM (1988) Release of multiple tachykinins from capsaicin-sensitive sensory nerves in the lung by bradykinin, histamine, dimethylphenyl piperazinium, and vagal nerve stimulation. Am Rev Respir Dis 137:1330-1335[ISI][Medline].
Simone DA, Ochoa JL (1991) Early and late effects of prolonged topical capsaicin on cutaneous sensibility and neurogenic vasodilatation in humans. Pain 47:285-293[ISI][Medline].
Simone DA, Ngeow JYF, Putterman GJ, LaMotte RH (1987) Hyperalgesia to heat after intradermal injection of capsaicin. Brain Res 418:201-203[ISI][Medline].
Simone DA, Baumann TK, LaMotte RH (1989) Dose-dependent pain and mechanical hyperalgesia in humans after intradermal injection of capsaicin. Pain 38:99-107[ISI][Medline].
Simone DA, Nolano M, Wendelschafer-Crabb G, Kennedy WR (1996) Intradermal injection of capsaicin in humans: diminished pain sensation associated with rapid degeneration of intracutaneous nerve fibers. Soc Neurosci Abstr 22:1802.
Szallasi A, Blumberg PM (1990a) Specific binding of resiniferatoxin, an ultrapotent capsaicin analog, by dorsal root ganglion membranes. Brain Res 524:106-111[ISI][Medline].
Szallasi A, Blumberg PM (1990b) Resiniferatoxin and its analogs provide novel insights into the pharmacology of the vanilloid (capsaicin) receptor. Life Sci 47:1399-1408[ISI][Medline].
Szolcsányi J (1977) A pharmacological approach to elucidation of the role of different nerve fibres and receptor endings in mediation of pain. J Physiol (Paris) 73:251-259[Medline].
Szolcsányi J (1993) Actions of capsaicin on sensory receptors. In: Capsaicin in the study of pain (Wood J, ed), pp 1-26. London: Academic.
Szolcsányi J, Janscó-Gábor A, Joó F (1975) Functional and fine structural characteristics of the sensory neuron blocking effect of capsaicin. Naunyn Schmiedebergs Arch Pharmacol 287:157-169[ISI][Medline].
Wang L, Hilliges M, Jernberg T, Wiegleb-Edstr&ouml;m D, Johansson O (1990) Protein gene product 9.5-immunoreactive nerve fibres and cells in human skin. Cell Tissue Res 261:25-33[ISI][Medline].
Wood JN, Winter J, James IF, Rang HP, Yeats J, Bevan S (1988) Capsaicin-induced ion fluxes in dorsal root ganglion cells in culture. J Neurosci 8:3208-3220[Abstract].

有奖活动:我为论坛出谋划策!! ←点击查看详情

您需要登录后才可以回帖 登录 | 会员注册

本版积分规则

收藏帖子 返回列表 联系我们 搜索 官方QQ群

QQ|关于我们|业务合作|手机版|新青年麻醉论坛 ( 浙ICP备19050841号-1 )

GMT+8, 2025-5-13 13:17 , Processed in 0.156476 second(s), 17 queries , Gzip On.

Powered by Discuz! X3.2

© 2001-2013 Comsenz Inc.

快速回复 返回顶部 返回列表